Baloxavir Marboxil for Uncomplicated Influenza Mechanism of Action & Side Effects(1) .pdf
Original filename: Baloxavir Marboxil for Uncomplicated Influenza Mechanism of Action & Side Effects(1).pdf
This PDF 1.5 document has been generated by Microsoft? Office Word 2007, and has been sent on pdf-archive.com on 06/12/2019 at 06:46, from IP address 198.11.x.x.
The current document download page has been viewed 60 times.
File size: 520 KB (3 pages).
Privacy: public file
Download original PDF file
Baloxavir Marboxil for Uncomplicated Influenza: Mechanism
of Action & Side Effects
With thousands of people getting the flu every year, and many people becoming
seriously ill, having safe and effective treatment alternatives is critical.
Baloxavir marboxil, marketed as Xofluza, is a first-in-class, one-dose oral agent first
approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza in
individuals 12 years and older, who have been symptomatic for less than 24 hours. It
is the first new antiviral with a novel mechanism of action to treat influenza in 20
Baloxavir vs Oseltamivir
Baloxavir marboxil differs from oseltamivir (marketed as Tamiflu, also available
generic) in its mechanism of action.
Influenza viral infection occurs when hemagglutinin on the envelope surface binds to
receptors on the cell surface of the human airway. Virus ribonucleoprotein (RNP)
complex is released in the intracellular space (shelling), and migrates into the
nucleus. Messenger RNA (mRNA) synthesis by viral RNA transcription and viral
genome RNA replication are separately promoted. As an RNA polymerase inhibitor,
baloxavir marboxil, inhibits mRNA synthesis. Viral polymerase consists of PA, PB1,
and PB2. Baloxavir marboxil hinders mRNA synthesis by inhibiting the capdependent endonuclease of PA, suppressing virus proliferation.
On the other hand, Oseltamivir inhibits the action of the viral enzyme
neuraminidase (which lets viruses bud and spread from the infected cell).
Baloxavir Marboxil Mechanism of Action, Image Source: nejm.org
Last year, Hayden and his colleagues published a study in the New England Journal of
Medicine that compared baloxavir with placebo and oseltamivir. The study found the
Baloxavir marboxil met its primary and secondary endpoints compared to placebo:
● Significantly reduced the duration of flu symptoms by more than one day (median
time 53.7 hours versus 80.2 hours; p<0.0001);
● Significantly reduced the duration of fever by nearly a day (median time 24.5 hours
versus 42.0 hours; p<0.0001);
● Significantly reduced the length of time viruses continued to be released from the
body (median time of viral shedding; 24.0 hours versus 96.0 hours; p<0.0001);
● Significantly reduced the levels of virus in the nose and throat from 24 hours through
Similar efficacy results were seen between baloxavir marboxil and oseltamivir in
relation to the duration of symptoms and fever reduction, but significant differences
were observed in time to cessation of viral shedding favoring baloxavir marboxil:
● No significant reduction in duration of symptoms (median time 53.5 hours versus 53.8
● No significant reduction in time to resolution of fever (median time 24.4 hours versus
24.0 hours; p=0.9225);
● Significantly reduced the length of time the virus continued to be released from the
body (viral shedding; 24.0 hours versus 72.0 hours; p<0.0001);
● Significantly reduced the levels of virus in the nose and throat at 24 hours and 72
Baloxavir marboxil was well-tolerated and had a numerically lower overall incidence
of adverse events (20.7 percent) reported compared with placebo (24.6 percent) or
oseltamivir (24.8 percent). The most common adverse events reported were
diarrhea (3.0 percent), bronchitis (2.6 percent), nausea (1.3 percent) and sinusitis
(1.1 percent), and all of these adverse events occurred at a lower frequency than
In addition, according to the Japan Times, NIID said that a mutant influenza virus
resistant to baloxavir was found in patients in December 2018. This is the first
influenza virus mutation discovered by a national research institution since the drug
was put into practical use.
In December 2018, two of four elementary school students in Yokohama were found
to be resistant to the Xofluza virus during a general screening after they had earlier
developed flu symptoms. The mutant virus is 76-120 times more resistant to the
drug than the unmutated virus detected by the other two children.
In clinical trials of the drug, drug-resistant viruses were detected in 23.4% of subjects
younger than 12 years of age.
Anyway, there will be challenges. It will take time to work through the difficulties.
Huateng Pharma, a professional manufacturer of pharmaceutical API and
intermediates, provides Baloxavir Marboxil key API and intermediates with high
Baloxavir Marboxil API: CAS NO. 1985606-14-1
Baloxavir Marboxil Intermediates: CAS:1985607-83-7, CAS: 1985607-70-2